Description:

Size: 100ul

Catalog no.: bs-1176R-A555

Price: 380 EUR

Product details

Modification Site

None

Target Antigen

Agrin

Gene ID Number

375790

Tested applications

IF(IHC-P)

French translation

anticorps

Crossreactivity

Mouse, Rat

Clonality

Polyclonal

Modification

Unmodified

Concentration

1ug per 1ul

Excitation emission

553nm/568nm

Conjugated with

ALEXA FLUOR® 555

Clone

Polyclonal antibody

Recommended dilutions

IF(IHC-P)(1:50-200)

Purification

Purified by Protein A.

Conjugation

Alexa Fluor,ALEXA FLUOR 555

Category

Conjugated Primary Antibodies

Host Organism

Rabbit (Oryctolagus cuniculus)

Also known as

Anti-Agrin PAb ALEXA FLUOR 555

Specificity

This is a highly specific antibody against Agrin.

Long name

Agrin Polyclonal Antibody, ALEXA FLUOR 555 Conjugated

Source

KLH conjugated synthetic peptide derived from mouse Agrin

Synonyms

AGRIN; Agrin proteoglycan; AGRN; FLJ45064; OTTHUMP00000044043; AGRIN_HUMAN; AGRIN_MOUSE.

Cross-reactive species details

Due to limited amount of testing and knowledge, not every possible cross-reactivity is known.

Storage conditions

Store this antibody in aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Keep refrigerated at 2 to 8 degrees Celcius for up to one year.

Properties

For facs or microscopy Alexa 1 conjugate.Very high photo stable ALEXA conjugate.If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies. ALEXA FLUOR they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.

Background of the antigen

Agrin is a neuronal aggregating factor that induces the aggregation of acetylcholine receptors and other postsynaptic proteins on muscle fibers and is crucial for the formation of the neuromuscular junction. Agrin is an essential extracellular matrix component which promotes clustering of nicotinic acetylcholine receptors (nAChRs) and other proteins during development at the neuromuscular junction. Agrin, MuSK and Rapsyn are all essential components for AChR aggregation, through an unknown mechanism. The C-terminal region of agrin is released into the medium, interacts with receptors on the muscle surface and induces AChR aggregation. The central region contains two O-linked glycosylation sites and a domain homologous to domain III of laminin. The N-terminal region anchors agrin to the extracellular matrix via other basal membrane components. This region also contains a protease inhibitor domain and glycosaminoglycan attachment sites; increasing the predicted MW from 200kDa to ~600kDa.